Sign in

    James Beer

    Research Analyst at William Blair

    James Beers is an Equity Research Analyst at William Blair specializing in coverage of the healthcare sector, with a particular focus on neurostimulation and medical device companies. He has directly covered firms such as Neuronetics Inc., participating in earnings calls and conducting in-depth company analyses, and is recognized for detailed research that informs investment strategies for institutional clients. Starting his analyst career in the healthcare domain, Beers joined William Blair prior to November 2024 after gaining relevant financial research experience, although previous employers and exact start dates are not publicly available. He holds relevant professional credentials for equity research analysts, including FINRA Series 7 and 63 licenses, and is known for his rigorous approach within the medical technology space.

    James Beer's questions to CUTR leadership

    James Beer's questions to CUTR leadership • Q1 2024

    Question

    Asked about the current macroeconomic and financing environment for capital equipment in aesthetics, and how to model capital revenue for the upcoming quarters.

    Answer

    The executive confirmed a challenging macro environment with difficult financing and sluggish practice volumes, particularly in the body contouring segment, which was anticipated in their guidance. For modeling, they expect a sequential increase in capital revenue from Q1 to Q2, with the second half of the year being stronger than the first, supported by the Xeo Plus launch and a strengthened sales team.

    Ask Fintool Equity Research AI